European Medical Solutions

Brussels Stock Exchange ALEMS.BR

European Medical Solutions Revenue for the year ending December 31, 2023: USD 44.77 M

European Medical Solutions Revenue is USD 44.77 M for the year ending December 31, 2023, a 12.93% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • European Medical Solutions Revenue for the year ending December 31, 2022 was USD 39.65 M, a -8.39% change year over year.
  • European Medical Solutions Revenue for the year ending December 31, 2021 was USD 43.28 M, a 9,770.32% change year over year.
  • European Medical Solutions Revenue for the year ending December 31, 2020 was USD 438.48 K, a -63.31% change year over year.
  • European Medical Solutions Revenue for the year ending December 31, 2019 was USD 1.19 M, a 82.94% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
Loading...
SV Wall Street
Brussels Stock Exchange: ALEMS.BR

European Medical Solutions

CEO Mr. Samuel Sancerni
IPO Date May 11, 2016
Location Belgium
Headquarters Avenue Louise 231
Employees 125
Sector Health Care
Industries
Description

European Medical Solutions engages in the design, development, and manufacturing of medical imaging systems for digital radiology and bone densitometry in Belgium. It offers R/F solutions, including PLATINUM NEO, a smart solution that revolutionizes the R/F workflow, as well as OPTIMA dRF, a robust solution; bone densitometry and body composition analysis equipment; chest and bone rooms, such as floor and ceiling tube stands; ambulatory radiography equipment; retrofit kits; C-ARM mobile operating room solutions; and mammography solutions. The company was formerly known as DMS Imaging SA and changed its name to European Medical Solutions in June 2024. DMS Imaging SA was founded in 1979 and is headquartered in Ixelles, Belgium. European Medical Solutions operates as a subsidiary of Diagnostic Medical Systems S.A.

StockViz Staff

February 6, 2025

Any question? Send us an email